NEW YORK (GenomeWeb) – NeoGenomics today reported a 26 percent year-over-year increase in first quarter revenues, including a 14 percent rise in testing revenue. 

For the three months ended March 31, the Ft. Myers, Fla.-based cancer genetics testing company posted $23 million in revenues, up from $18.2 million in the year-ago quarter. During the recently completed quarter, NeoGenomics performed 49,396 tests for $20.7 million in testing revenues, compared to 38,734 million tests and $18.2 million in testing revenues in the year-ago period. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.